Malaysia Kidney Cancer Therapeutics Market Report 2023 to 2030

Malaysia Kidney Cancer Therapeutics Market Analysis

$ 3999

The Malaysia Kidney Cancer Therapeutics Market was valued at $10.11 Mn in 2023 and is predicted to grow at a CAGR of 5.06% from 2023 to 2030, to $14.29 Mn by 2030. The key drivers of this industry include the increasing prevalence of kidney cancer due to lifestyle and environmental factors, early detection, and advancement in diagnostic tools. The key players in the industry are Pfizer, Bayer, Novartis, Roche, Bristol Myers Squibb, and AstraZeneca among others.

CATEGORY: Pharmaceuticals GEOGRAPHY: Malaysia AUTHOR: Avantika Gupta

Buy Now

Malaysia Kidney Cancer Therapeutics Market Executive Summary

The Malaysia Kidney Cancer Therapeutics Market is at around $10.11 Mn in 2023 and is projected to reach $14.29 Mn in 2030, exhibiting a CAGR of 5.06% during the forecast period.

Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grow out of control, forming a tumor. The two most common types of kidney cancers are renal cell carcinoma (RCC), and Transitional cell carcinoma (TCC), accounting for the majority of the remainder. Other less common types of kidney cancers include Renal sarcoma and Wilms tumor. The causes of kidney cancer are not fully understood, although risk factors include smoking, obesity, high blood pressure, a sedentary lifestyle, and a family history of the disease. Other symptoms may include unexpected weight loss, exhaustion, recurrent fever or night sweats, and anemia. Imaging studies such as CT scans or MRIs are often used to make a diagnosis, which is then confirmed with a biopsy. Treatment approaches depend on the stage and grade of cancer. Common treatments include surgical removal of the tumor or entire kidney (nephrectomy), medication (including targeted therapy, which attacks cancer cells' specific weaknesses, and immunotherapy, which aids your immune system in fighting cancer), and ablation techniques, which use extreme heat, cold, or radio waves to destroy cancer cells.

Kidney cancer is the ninth most common neoplasm in men and not that common in women in Malaysia. Renal carcinoma is rare and affects approximately 1.9 per 100,000 persons in Malaysia. The market therefore is driven by significant factors like the increasing prevalence of kidney cancer due to lifestyle and environmental factors, supportive government initiatives, and improved diagnosis with better imaging techniques. However, high costs of treatment, stringent regulatory requirements, and side effects associated with the drugs restrict the growth of the market.

Leading players include Pfizer, known for its advancements in targeted therapies, and Bristol Myers Squibb, with a strong portfolio of immunotherapy drugs for advanced stages. Other contributors to the development of treatment for kidney cancer include Merck & Co., Roche, and Novartis.

Market Dynamics

Market Growth Drivers

Early detection: Early detection allows for a wider range of treatment options, often with less invasive procedures and higher success rates. If a tumor is caught early, complete surgical removal might be possible, leading to a much better prognosis. Implementing diagnostic programs with regular checkups, and imaging tests like ultrasounds or CT scans can significantly increase the chances of early discovery.

Increasing Incidence and Prevalence: The global occurrence of kidney cancer is growing, even in Malaysia. There are 31,633 deaths annually due to cancer in Malaysia, out of which Kidney cancer has a prevalence rate of 2.2%. Factors such as the aging population, lifestyle changes, and improved diagnostic techniques contribute to the increased detection of kidney cancer cases. Environmental exposures to toxins like herbicides, industrial chemicals, and air pollution are also emerging as potential contributors.

Technological advancements: Progress in drug development has helped with the introduction of targeted therapies, immunotherapies, and combination regimens for effective treatment. These innovative treatments offer several advantages over traditional chemotherapy. Targeted therapies and immunotherapies work by attacking cancer cells or the body's immune system, minimizing damage to healthy tissues, and reducing side effects. Combination regimens, where multiple drugs are used, can further enhance treatment efficacy.

Government initiatives: The Ministry of Health Malaysia established the NCCP as a thorough program to coordinate cancer control efforts. It centers on providing prevention, early detection, treatment, and palliative care for individuals with cancer. The government initiates efforts to increase knowledge on healthy living, steps to prevent cancer, and the significance of early detection. Astellas Pharma Inc. is enhancing initiatives for cancer control in Malaysia.

Market Restraints

High cost of treatment: Cancer drugs, particularly newer targeted therapies and immunotherapies, come with a hefty price tag. These costs can place a significant financial burden on patients and healthcare systems. While these medications offer improved efficacy, the high cost can limit access for some patients. This can lead to difficult choices for individuals and families, potentially affecting treatment adherence and ultimately impacting treatment outcomes.

Regulatory Hurdles: Malaysia's strict regulatory processes can significantly delay approval for new kidney cancer medications. This lag prevents patients from receiving these potentially life-saving treatments. Additionally, the delay restricts the market potential for these drugs in Malaysia, hindering pharmaceutical companies' ability to recoup their investment.

Side effects: Targeted therapies and immunotherapies, while offering significant advantages over traditional chemotherapy, are not without their drawbacks. These treatments can have significant adverse effects and safety concerns. Immunotherapy, on the other hand, may lead to immune-related toxicities, where the body's immune system attacks healthy tissues along with cancer cells. Careful patient monitoring and management of these side effects is essential to minimize their impact and ensure patient well-being.

Healthcare Infrastructure and Resources: Variations in healthcare infrastructure and resources in different areas of Malaysia could impact the accessibility and administration of medications for kidney cancer. Areas with limited access to these resources may face challenges in providing proper care. This scarcity hampers the ability to efficiently diagnose and treat patients, consequently affecting overall market growth.

Regulatory Landscape and Reimbursement Scenario

The regulatory landscape for cancer drugs in Malaysia is overseen primarily by the Malaysian regulatory authority, the National Pharmaceutical Regulatory Agency (NPRA), which operates under the Ministry of Health. NPRA is responsible for ensuring drug safety, quality, and efficacy through the evaluation of scientific data. It monitors the quality of pharmaceutical products already on the market.

In Malaysia, there are several health insurance schemes to provide financial protection such as MySalam is a national health protection scheme that provides financial assistance to low-income households and B40 (bottom 40%) income group individuals

The process of obtaining a license for drugs and pharmaceuticals in Malaysia involves a comprehensive process overseen by NPRA. The registration process involves the submission of comprehensive dossiers containing preclinical and clinical data, manufacturing information, and quality control documentation. The NPRA monitors the safety and effectiveness of cancer drugs through post-marketing surveillance activities

Competitive Landscape

Key Players

Here are some of the major key players in the Malaysia Kidney Cancer Therapeutics Market:

Pfizer
Roche
Bistrol Meyers Squibb
Novartis
Merck
AstraZeneca
Eisai
Ipsen
Dr. Reddy's Laboratories Ltd
Bayer

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Malaysia Kidney Cancer Therapeutics Market Segmentation

By Cancer Type

Clear cell RCC
Papillary RCC
Chromophobe RCC
Transitional cell carcinoma
Other Kidney cancers (Wilms tumor, Renal sarcoma, Collecting duct RCC)

By Treatment Type

Targeted Therapy
Immunotherapy
Surgery
Radiation Therapy

By Drug Classification

Angiogenesis Inhibitors
Monoclonal Antibodies
mTOR Inhibitors
Cytokine Immunotherapy (IL-2)

By Distribution Channel

Hospitals
Homecare
Specialty Clinics

Insights10 will provide you with the reports within 10 key parameters which are:

Market Overview
Market Growth Drivers & Restraints
Epidemiology of Disease Type
Market Segmentation
Market Share
Competitive Landscape
Key Company Profiles
Healthcare Policies & Regulatory Framework
Reimbursement Scenario
Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

Establishing market drivers and trends
Analyzing the regulatory landscape to understand future growth
Market Segment based analysis to obtain revenue/volume
Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to oﬀer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.